Dishman Carbogen receives EIR from USFDA for Bavla facility

29 Jan 2019 Evaluate

Dishman Carbogen Amcis has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Bavla facility, after successfully inspected by the USFDA in October 2018.

Thus, the company's facilities in Bavla and Naroda in India, multiple facilities in Switzerland and the Netherlands continue to be approved by the USFDA.

Dishman Carbogen Amcis provides innovative solutions for the development and supply of drug substances and drug products to the pharmaceutical and biopharmaceutical industries.

Dishman Carbogen Amc Share Price

254.65 -2.30 (-0.90%)
02-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.35
Dr. Reddys Lab 1255.45
Cipla 1510.95
Zydus Lifesciences 916.50
Lupin 2105.85
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×